A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins

Oncotarget. 2015 Oct 13;6(31):30919-28. doi: 10.18632/oncotarget.5130.

Abstract

We have created a novel fluorescent model of a human ovarian carcinoma xenograft overexpressing receptor HER2, a promising molecular target of solid tumors. The model is based on a newly generated SKOV-kat cell line stably expressing far-red fluorescent protein Katushka. Katushka is most suitable for the in vivo imaging due to an optimal combination of high brightness and emission in the "window of tissue transparency". The relevance of the fluorescent model for the in vivo monitoring of tumor growth and response to treatment was demonstrated using a newly created HER2-targeted recombinant immunotoxin based on the 4D5scFv antibody and a fragment of the Pseudomonas exotoxin A.

Keywords: HER2; far-red fluorescent protein; immunotoxin; ovarian carcinoma; xenograft tumor model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Apoptosis
  • Cell Proliferation
  • Cisplatin / pharmacology
  • Disease Models, Animal*
  • Female
  • Fluorescent Antibody Technique / methods*
  • Humans
  • Immunotoxins / chemistry
  • Immunotoxins / pharmacology*
  • Luminescent Proteins / genetics
  • Luminescent Proteins / metabolism*
  • Mice
  • Microscopy, Confocal
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / pathology
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Recombinant Fusion Proteins / pharmacology*
  • Red Fluorescent Protein
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Immunotoxins
  • Luminescent Proteins
  • Recombinant Fusion Proteins
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Cisplatin